These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 17389892)

  • 1. Osteomalacia in a hemodialysis patient receiving an active vitamin D sterol.
    Hernandez JD; Wesseling K; Boechat MI; Gales B; Salusky IB
    Nat Clin Pract Nephrol; 2007 Apr; 3(4):227-32. PubMed ID: 17389892
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intravenous paricalcitol for treatment of secondary hyperparathyroidism in children on hemodialysis.
    Greenbaum LA; Benador N; Goldstein SL; Paredes A; Melnick JZ; Mattingly S; Amdahl M; Williams LA; Salusky IB
    Am J Kidney Dis; 2007 Jun; 49(6):814-23. PubMed ID: 17533024
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Emerging role for the vitamin D receptor activator (VDRA), paricalcitol, in the treatment of secondary hyperparathyroidism.
    Cozzolino M; Brancaccio D
    Expert Opin Pharmacother; 2008 Apr; 9(6):947-54. PubMed ID: 18377338
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Beneficial effects of better control of secondary hyperparathyroidism with paricalcitol in chronic dialysis patients.
    Capuano A; Serio V; Pota A; Memoli B; Andreucci VE
    J Nephrol; 2009; 22(1):59-68. PubMed ID: 19229819
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oral paricalcitol for the treatment of secondary hyperparathyroidism in patients on hemodialysis or peritoneal dialysis.
    Ross EA; Tian J; Abboud H; Hippensteel R; Melnick JZ; Pradhan RS; Williams LA; Hamm LL; Sprague SM
    Am J Nephrol; 2008; 28(1):97-106. PubMed ID: 17914251
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevalence of vitamin D [25(OH)D] deficiency and effects of supplementation with ergocalciferol (vitamin D2) in stage 5 chronic kidney disease patients.
    Blair D; Byham-Gray L; Lewis E; McCaffrey S
    J Ren Nutr; 2008 Jul; 18(4):375-82. PubMed ID: 18558303
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mortality risk among hemodialysis patients receiving different vitamin D analogs.
    Tentori F; Hunt WC; Stidley CA; Rohrscheib MR; Bedrick EJ; Meyer KB; Johnson HK; Zager PG;
    Kidney Int; 2006 Nov; 70(10):1858-65. PubMed ID: 17021609
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomised clinical study of alfacalcidol and paricalcitol.
    Hansen D
    Dan Med J; 2012 Feb; 59(2):B4400. PubMed ID: 22293059
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevalence of vitamin D deficiency and the safety and effectiveness of monthly ergocalciferol in hemodialysis patients.
    Saab G; Young DO; Gincherman Y; Giles K; Norwood K; Coyne DW
    Nephron Clin Pract; 2007; 105(3):c132-8. PubMed ID: 17228173
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Paricalcitol-treated patients experience improved hospitalization outcomes compared with calcitriol-treated patients in real-world clinical settings.
    Dobrez DG; Mathes A; Amdahl M; Marx SE; Melnick JZ; Sprague SM
    Nephrol Dial Transplant; 2004 May; 19(5):1174-81. PubMed ID: 15004264
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Switch from calcitriol to paricalcitol in secondary hyperparathyroidism of hemodialysis patients: Responsiveness is related to parathyroid gland size.
    Vulpio C; Maresca G; Distasio E; Cacaci S; Panocchia N; Luciani G; Bossola M
    Hemodial Int; 2011 Jan; 15(1):69-78. PubMed ID: 21223484
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumor-induced osteomalacia: the importance of measuring serum phosphorus levels.
    Halperin F; Anderson RJ; Mulder JE
    Nat Clin Pract Endocrinol Metab; 2007 Oct; 3(10):721-5. PubMed ID: 17893691
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of Paricalcitol on Bone Density After Kidney Transplantation: Analysis of 2 Transplant Centers.
    Žilinská Z; Dedinská I; Breza J; Laca L
    Iran J Kidney Dis; 2017 Nov; 11(6):461-466. PubMed ID: 29190607
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Management of secondary hyperparathyroidism in uremic patients: the role of the new vitamin D analogs.
    Brancaccio D; Cozzolino M; Galassi A; Chiarelli G; Butti A; Bellasi A; Rocca-Rey L; Volpi A; Anelli A; Zoni U; Fusaro M; Brambilla C; Missaglia E; Crovetto C; Russo M; Longhini C; Provenzano R; Incalcaterra F; Cerasola G; Li Vecchi M; Gallieni M
    J Nephrol; 2007; 20(1):3-9. PubMed ID: 17347966
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Opposite effects of calcitriol and paricalcitol on the parathyroid hormone-(1-84)/large carboxy-terminal-parathyroid hormone fragments ratio in patients with stage 5 chronic kidney disease.
    Monier-Faugere MC; Mawad H; Malluche HH
    Clin J Am Soc Nephrol; 2007 Nov; 2(6):1255-60. PubMed ID: 17942766
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Role of paracalcitol in the management of non-dialysis CKD: state of art and... Unmet needs].
    Mascia S; Garofalo C; Donnarumma G; Di Pietro R; Liberti ME; Pacilio M; Sagliocca A; Zamboli P; Minutolo R; Conte G; De Nicola L
    G Ital Nefrol; 2010; 27(6):616-28. PubMed ID: 21132644
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oral paricalcitol in the treatment of patients with CKD and proteinuria: a randomized trial.
    Fishbane S; Chittineni H; Packman M; Dutka P; Ali N; Durie N
    Am J Kidney Dis; 2009 Oct; 54(4):647-52. PubMed ID: 19596163
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of 22-oxacalcitriol and calcitriol on PTH secretion and bone mineral metabolism in a crossover trial in hemodialysis patients with secondary hyperparathyroidism.
    Ogata H; Koiwa F; Shishido K; Takahashi K; Ito H; Kinugasa E; Taguchi S
    Ther Apher Dial; 2007 Jun; 11(3):202-9. PubMed ID: 17498002
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Changes in fibroblast growth factor 23 during treatment of secondary hyperparathyroidism with alfacalcidol or paricalcitol.
    Hansen D; Rasmussen K; Pedersen SM; Rasmussen LM; Brandi L
    Nephrol Dial Transplant; 2012 Jun; 27(6):2263-9. PubMed ID: 22140123
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.